👉⭐️Truly thrilled to see this in press- Rux-before, during, after-HCT for MF = very low GVHD and excellent PFS/OS. Thank you to all the sites, PIs, Incyte for supporting this and most of all our patients! JCO OA 😀 https://t.co/4PmiFvLVmM #MPNSM #MGH

CONGRESS | #Tandem25 | PRESENTATION Yi-Bin Chen, @harvardmed, provides insights into the role of MRD testing in post-HCT maintenance for AML. He discusses various maintenance treatment options, including FLT3 inhibitors, HMAs, IDH1/2 inhibitors, and menin inhibitors, and their

Ruxolitinib therapy was associated with improvements in lung function for participants with BOS. https://t.co/0RyoljJKA5 #clinicaltrialsandobservations #transplantation

Gain insight on cutting-edge clinical evidence supporting targeted, immune & cell-based strategies for the prevention & treatment of #GVHD with Drs Zachariah DeFilipp (@DrZackDeFilipp), & Betty K. Hamilton (@hamiltkyb), on 2/14 at 6:30 AM HST. https://t.co/s9MeUdkDLq #Tandem25

Allogeneic Hematopoietic Cell Transplantation for Severe Aplastic Anemia: Evidence-Based Guidelines From the American Society for Transplantation and Cellular Therapy If no matched donor then upfront Haplo BMT an option now #PTCyRules #ASH24

CONGRESS | #cGvHD2024 @DrZackDeFilipp spoke about the treatment of cGvHD from the 2020 NIH consensus. Larger trials lack correlative analyses, and there is a need for innovative trial design. Steroid-free monotherapies in the first line are lacking but should remain a long-term

A study in patients with chronic GVHD evaluated three doses of axatilimab, a colony-stimulating factor 1 receptor antibody. The lowest dose appeared to maximize response with the fewest adverse effects. Full AGAVE-201 trial results: https://t.co/Amq39yLRo2

Initial treatment with third-party FMT and corticosteroids is associated with high response rates in LGI acute GVHD. https://t.co/q33No2sgJK #transplantation

@DrZackDeFilipp , 3rd party FMT for high risk LGI GVHD n=10, 9/10 completed all doses, 70% response rate at D28, increase in alpha diversity after FMT, expansion of donor derived species in recipients post FMT. https://t.co/ol6RAuu08u

New therapeutics are showing promise for #GVHD treatment! Hear the latest data in our new CME/MOC activity, presented by @DrZackDeFilipp

#ICYMI: Watch our free #CME program on-demand to review the efficacy of existing and emerging therapies for chronic Graft-versus-Host Disease (#GvHD) ➡️ https://t.co/rfxzR1bQfQ Discussion led by @DrZackDeFilipp, MD and Andrew Rogers, MD, MS #MedEd #MedicalEducation

Coming soon! Join @DrZackDeFilipp and Dr. Andrew Rogers to review new data on existing and emerging therapeutic approaches for chronic #GvHD and their application in academic and community settings ➡️ https://t.co/6SI2ZD6gtJ #FreeCME #MedEd #CME

Despite new therapeutic agents and ongoing research in #GvHD, significant disease burden is common. Join @DrZackDeFilipp during our free #CME program with @RareDiseases to discuss effective strategies for improving patient #QoL ➡️ https://t.co/0maiWvxSD1 #RareDiseases #MedEd

CONGRESS #ASH23 | @DrZackDeFilipp @MGHCancerCenter shares data from a phase II trial of ruxolitinib for the treatment of BOS following allo-HCT. Results show meaningful clinical responses in BOS across all severity levels, with low levels of severe AEs, supporting the use of

Congratulations to Yi-Bin Chen, MD on his promotion to Full Professor at @harvardmed! We are grateful for his contributions, vision, and leadership to the field of hematopoietic stem cell transplantation (HSCT) and the @MassGeneralNews Transplant and Cellular Therapy Program.

How can blood biomarkers supplement clinical prediction models at GVHD onset? A 🧵 for our fresh study:

Now out in Intensive Care Medicine - our work to validate EASIX for prediction of sepsis in patients receiving alloSCT. Great 🇩🇪🇺🇸teamwork & collab @med5_ukhd, @DrZackDeFilipp, Yi-Bin Chen, @MarcelaMaus, BMT @MGHCancerCenter #bmtsm

I had fun recording this with my friend and former office mate @andrewbrunner

THREE DOWN ✅✅✅ #BeatPHILA

The composition of the intestinal #microbiome may predict clinical outcomes of CAR T cell therapy for #lymphoma, which could inform microbiota-based intervention strategies. Read our latest News and Views from @MarcelaMaus & @DrZackDeFilipp @harvardmed https://t.co/bPQjgVyza3